Hunan Er-Kang Pharmaceutical (300267) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hunan Er-Kang Pharmaceutical (300267) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.0B, trading at ¥2.91 on the SHZ. This SniperIQ fundamentals page covers Hunan Er-Kang Pharmaceutical's valuation, profitability (net margin -37.3%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hunan Er-Kang Pharmaceutical's market cap?
Hunan Er-Kang Pharmaceutical (300267) has a market capitalization of approximately ¥6.0B, trading at ¥2.91 on the SHZ. Market cap moves with the live share price.
What is Hunan Er-Kang Pharmaceutical's P/E ratio?
Hunan Er-Kang Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hunan Er-Kang Pharmaceutical?
Hunan Er-Kang Pharmaceutical runs a net profit margin of -37.3%, a gross margin of 26.6%, and an operating margin of -34.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hunan Er-Kang Pharmaceutical generate?
Hunan Er-Kang Pharmaceutical reported revenue of ¥1.2B for fiscal year 2025, with net income of -¥380M and earnings per share (EPS) of -0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hunan Er-Kang Pharmaceutical pay a dividend?
Hunan Er-Kang Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hunan Er-Kang Pharmaceutical financially healthy?
Hunan Er-Kang Pharmaceutical carries a debt-to-equity ratio of 0.18x and a current ratio of 2.09x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hunan Er-Kang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hunan Er-Kang Pharmaceutical (300267) the key facts are: market cap ¥6.0B, revenue ¥1.2B, 52-week range 2.78-5.11. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hunan Er-Kang Pharmaceutical's full fundamentals live
Get Hunan Er-Kang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.